UBS Group Initiates Coverage on Ascendis Pharma A/S (NASDAQ:ASND)

UBS Group began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report sent to investors on Tuesday, Marketbeat reports. The firm issued a buy rating and a $196.00 price target on the biotechnology company’s stock.

ASND has been the subject of a number of other reports. Stifel Nicolaus lifted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. JPMorgan Chase & Co. lowered their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. TD Cowen decreased their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, Citigroup boosted their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $192.07.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $134.43 on Tuesday. The business has a fifty day moving average of $132.53 and a 200-day moving average of $133.60. The firm has a market cap of $8.16 billion, a PE ratio of -16.64 and a beta of 0.65. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $60,000. Janus Henderson Group PLC grew its holdings in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.